当前位置:
X-MOL 学术
›
Cell Metab.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Targeting Synaptic NMDA Receptor Co-agonism as a Therapy for Alzheimer’s Disease?
Cell Metabolism ( IF 27.7 ) Pub Date : 2020-03-03 , DOI: 10.1016/j.cmet.2020.02.009 Giles E. Hardingham
中文翻译:
靶向突触NMDA受体协同作用作为阿尔茨海默氏病的治疗方法?
更新日期:2020-03-03
Cell Metabolism ( IF 27.7 ) Pub Date : 2020-03-03 , DOI: 10.1016/j.cmet.2020.02.009 Giles E. Hardingham
Alzheimer’s disease (AD) is associated with lower brain glucose metabolism. In this issue, Le Douce et al. (2020) show that this leads to insufficient astrocyte-dependent production of D-serine, co-agonist of synaptic NMDA receptors. Oral L-serine therapy rescues NMDA receptor hypofunction, plasticity, and cognition in an AD model, suggesting a new therapeutic strategy.
中文翻译:
靶向突触NMDA受体协同作用作为阿尔茨海默氏病的治疗方法?
阿尔茨海默氏病(AD)与较低的大脑葡萄糖代谢有关。在本期中,Le Douce等人。(2020)表明,这导致不足的星形胶质细胞依赖的D-丝氨酸,突触NMDA受体的共同激动剂的生产。口服L-丝氨酸疗法可挽救AD模型中的NMDA受体功能低下,可塑性和认知能力,提示新的治疗策略。